A Colombian cannabis producer has completed the country\u2019s first commercial export of CBD isolate to Europe after its shipment arrived safely in Switzerland.\r\n\r\nThe Colombian government granted its first CBD isolate export permit to PharmaCielo (TSXV: PCLO) last month, and the firm has moved quickly to begin supplying the lucrative European market. It has now shipped its first batch to the Swiss office of Creso Pharma, an Australian pharmaceutical company it is in the process of purchasing for AU$122 million.\r\n\r\nDavid Attard, chief executive at PharmaCielo, said the inaugural shipment was \u201csymbolic on many levels\u201d.\r\n\r\n\u201cPharmaCielo is the first medicinal cannabis company to commercially export cannabis derived isolates from\u00a0Colombia\u00a0to\u00a0Switzerland, the global capital of the pharma industry,\u201d he said. Particularly pleasing is the fact that the first batch we ever exported went to Creso Pharma, our trusted partner soon to be part of our Company.\u201d\r\n\r\nPharmaCielo is headquartered in Ontario, but it bills itself as Colombia\u2019s premier cultivator and producer of medicinal-grade cannabis oil. It recently announced a sales agreement covering Uruguay, Paraguay, Bolivia, and southern Brazil with distributor Laboratorios Adler, and now it is targeting Europe too.\r\n\r\nCreso Pharma is an Australian company, but its main operation is in Switzerland and it also has cultivation facilities in Canada, Colombia, and Israel. The firm has listings in 13 countries for its range of products.\r\n\r\nIts board has endorsed PharmaCielo\u2019s takeover and it is due to close next month. The idea is to create a vertically integrated global supply chain, with operations in North America, South America, Europe, the Middle East, Australia, and New Zealand.\r\n\r\nWhen the deal is complete, Creso shareholders will hold around 13% of the capital in the merged entity, while Creso co-founder and chief executive Miri Halperin will join the board.\r\n\r\nBut the two firms are already benefiting from synergies, as Laboratorios Adler has agreed to sell Creso\u2019s products in Latin America, while Creso is now distributing PharmaCielo\u2019s products in Europe after receiving the CBD isolate.\r\n\r\nColombia is shaping up to be a major supplier within the global marijuana industry, due to the favourable growing conditions and cheap labour costs, so many North American operators are piling in.